{
    "organizations": [],
    "uuid": "d65c6e504c67e6eae8fea28baa279a6e20e27530",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-evotec-and-celgene-enter-into-stra/brief-evotec-and-celgene-enter-into-strategic-oncology-partnership-idUSASO00051G",
    "ord_in_thread": 0,
    "title": "BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Evotec Ag:\n* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP\n* UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MILLION\n* CELGENE RECEIVES EXCLUSIVE OPT-IN RIGHTS TO LICENSE WORLDWIDE RIGHTS TO ALL PROGRAMMES DEVELOPED WITHIN THIS COLLABORATION\n* EVOTEC MAY BE ELIGIBLE TO RECEIVE SIGNIFICANT MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON EACH LICENSED PROGRAMME Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-22T03:38:00.000+03:00",
    "crawled": "2018-05-22T19:20:09.043+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "evotec",
        "ag",
        "evotec",
        "celgene",
        "enter",
        "strategic",
        "oncology",
        "partnership",
        "term",
        "agreement",
        "evotec",
        "receive",
        "upfront",
        "payment",
        "million",
        "celgene",
        "receives",
        "exclusive",
        "right",
        "license",
        "worldwide",
        "right",
        "programme",
        "developed",
        "within",
        "collaboration",
        "evotec",
        "may",
        "eligible",
        "receive",
        "significant",
        "milestone",
        "payment",
        "well",
        "tiered",
        "royalty",
        "licensed",
        "programme",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}